QNZ46

Overview

QNZ46 is a highly selective noncompetitive NMDA receptor antagonist targeting GluN2C/D ( IC 50 =3.9 μM), GluN1/GluN2C ( IC 50 =7.1 μM), and GluN1/GluN2D ( IC 50 =182 μM) subunits. QNZ46 inhibits glutamate-mediated calcium influx, thereby blocking excitotoxicity. QNZ46 is membrane permeable and can cross the blood-brain barrier, where it inhibits myelin damage and axonal degeneration.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Depression | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > iGluR

Product Information

• Catalog No.: HY-15703
• CAS No.: 1237744-13-6
• Molecular Formula: C24H17N3O6
• Molecular Weight: 443.41
• Purity: 99.46%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Availability: In-stock

Source

Original product source